MAP2K7 and melanoma: This review focuses on the current landscape of resistance with the chronic use of BRAF and MEK inhibitors in BRAF -mutant melanoma and progress made in the fields of immunotherapies and other small molecules when used alone or in combination with BRAF and MEK inhibitors to delay or circumvent the onset of resistance for patients with stage III/IV melanoma.